Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Microbix Biosystems has established a team of experts to help manufacturers boost their production of influenza vaccine.

Microbix Develops Team to Help Boost Flu Vaccine Production

Johnson & Johnson consolidates operations, Xceleron leases new facility, more

August 2, 2007 Notes: Johnson & Johnson Consolidates Operations, Xceleron Leases New Facility, More

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

A spate of drugs are scheduled to come off patent, offering vast potential and competition.

Favorable Outlook for Generic APIs

Motonari Deguchi works in the Microbial Control Department at Shibuya Kogyo Co., Ltd. in Kanazawa, Japan.

Mayumi Maruyama works in the Microbial Control Department at Shibuya Kogyo Co., Ltd. in Kanazawa, Japan.

Tomoo Matsuoka works in the Microbial Control Department at Shibuya Kogyo Co., Ltd. in Kanazawa, Japan.

James E. Akers is the president of Akers Kennedy & Associates, PO Box 22562, Kansas City, MO 64113, akainckc@aol.com.

This article presents a study of an aseptic environmental monitoring system for surface contamination at critical areas using a robot.

The Application of Robotics to Aseptic Environmental Surface Monitoring

Merck & Co. acquires NovaCardia, Sanofi Pasteur completes vaccine-manufacturing facility, more

July 27, 2007 Notes: Merck & Co. Acquires NovaCardia, Sanofi Pasteur Completes Vaccine-Manufacturing Facility, More

Angie Drakulich was editorial director of Pharmaceutical Technology.

Novartis Vaccines plans to produce approximately 40 million doses of its ?Fluvirin? vaccine for distribution in the United States during the 2007?2008 flu season.

Novartis to Increase US Influenza Vaccine Supplies

Michelle Hoffman, editorial director of Pharmaceutical Technology.

A new guidance issued by the US Food and Drug Administration earlier this month advises companies on how to treat polymorphic drug compounds?those that exhibit multiple structural forms?in filing abbreviated new drug applications.

New FDA Guidance on Polymorphic Compounds in Generic Drugs

Novartis Vaccines and Diagnostics, a division of Novartis AG (Basel, Switzerland) and IntercellAG (Vienna, Austria), a biotechnology company, will collaborate toward developing a broad range of vaccines.

Novartis and Intercell Partner for Novel Vaccine Development

... the biotech industry could make characterization of its products easier by paying more attention to downstream processing and purification issues, creating a cleaner product that is easier to identify.

Profiling biopharma medicines

Washington, DC (June 14)-The US Department of Health and Human Services awarded two contracts totaling $132.5 million to Sanofi Pasteur and MedImmune to retrofit their influenza vaccine manufacturing facilities.